Arihant Capital Markets receives no-objection from exchanges for composite scheme
Arihant Capital Markets received 'no adverse observations' from BSE and 'no objection' from NSE on June 25, 2026, for its composite scheme of arrangement involving five entities. The exchanges mandated compliance with SEBI LODR regulations, including disclosures on financials, liabilities, and shareholding patterns. Arihant Elite Financial Solutions Limited must list its securities within 60 days of the NCLT order.

*this image is generated using AI for illustrative purposes only.
Arihant Capital Markets Ltd received 'no adverse observations' from BSE Limited and 'no objection' from the National Stock Exchange of India Limited on June 25, 2026, for its composite scheme of arrangement. The exchanges issued observation letters enabling the company to proceed with filing the draft scheme with the National Company Law Tribunal (NCLT), subject to compliance with specific conditions. The scheme involves Arihant Financial Services Limited, Arihant Capital Markets Limited, Arihant Elite Financial Solutions Limited, Arihant Investment Banking Services Limited, and Arihant Money Marvel Wealth Management Limited.
The observation letters from both exchanges outline mandatory compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company must ensure the scheme adheres to Regulation 11 of the LODR Regulations and discloses all details of ongoing adjudication, recovery proceedings, and enforcement actions against the company, its promoters, and directors to the NCLT and shareholders. Additionally, any changes to the draft scheme require specific written consent from SEBI.
Regulatory Conditions and Disclosures
The exchanges have stipulated comprehensive disclosure requirements to be included in the explanatory statement sent to shareholders. These disclosures are intended to enable informed decision-making and include:
- A small explanation of the scheme, the rationale, synergies, and a cost-benefit analysis.
- Details of the Registered Valuer and Merchant Banker, along with the summary of methods used to determine the share-swap ratio.
- Latest financials of all involved companies not older than six months from the date of the stock exchange's No Objection Certificate (NOC).
- Pre and post-scheme shareholding patterns and capital build-up for the last three years.
- Quantitative details of the impact on reserves for all entities involved.
Listing and Operational Requirements
Arihant Elite Financial Solutions Limited (AEFSL) is advised to complete the listing of its securities and commence trading within sixty days of receiving the NCLT order. The validity of the observation letters is six months from June 25, 2026, within which the scheme must be submitted to the NCLT. The exchanges reserve the right to withdraw their observations if any information provided is found to be incomplete or misleading.
| Entity | Role in Scheme | Key Requirement |
|---|---|---|
| Arihant Financial Services Limited | Transferor Company 1 | Transfer liabilities to Transferee Company |
| Arihant Capital Markets Limited | Transferee Company 1 / Demerged Company | File scheme with NCLT within 6 months |
| Arihant Elite Financial Solutions Limited | Resulting Company / Transferor Company 2 | Complete listing within 60 days of NCLT order |
| Arihant Investment Banking Services Limited | Transferee Company 2 | Comply with disclosure norms |
| Arihant Money Marvel Wealth Management Limited | Transferee Company 3 | Comply with disclosure norms |
Historical Stock Returns for Arihant Capital Markets
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.02% | -1.62% | +0.16% | -25.56% | -20.50% | +170.09% |
How will the composite scheme of arrangement impact the consolidated capital structure and earnings per share of Arihant Capital Markets post-NCLT approval?
What specific synergies and cost-benefit advantages does the company anticipate from the merger of these five entities?
What is the expected timeline for the NCLT approval process, and are there potential regulatory hurdles that could delay the filing?































